These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32299770)

  • 1. Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor.
    Robert L; Langner-Lemercier S; Angibaud A; Sale A; Thepault F; Corre R; Lena H; Ricordel C
    Clin Lung Cancer; 2020 Sep; 21(5):e474-e477. PubMed ID: 32299770
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
    Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
    J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
    Sanchis-Borja M; Ricordel C; Chiappa AM; Hureaux J; Odier L; Jeannin G; Descourt R; Gervais R; Monnet I; Auliac JB; Chouaïd C
    Lung Cancer; 2020 May; 143():36-39. PubMed ID: 32200139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
    Richard K; Weslow J; Porcella SL; Nanjappa S
    Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
    Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer.
    Wang J; Zheng Q; Chen J
    Immunotherapy; 2023 Apr; 15(6):409-416. PubMed ID: 36950965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage.
    Conde-Estévez D; Monge-Escartín I; Ríos-Hoyo A; Monzonis X; Echeverría-Esnal D; Moliner L; Duran-Jordà X; Taus Á; Arriola E
    J Chemother; 2021 Feb; 33(1):32-39. PubMed ID: 33267748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
    Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
    JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
    Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients.
    Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
    Anticancer Drugs; 2020 Sep; 31(8):872-875. PubMed ID: 32796406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.
    Fournel L; Boudou-Rouquette P; Prieto M; Hervochon R; Guinet C; Arrondeau J; Alexandre J; Damotte D; Wislez M; Batteux F; Icard P; Goldwasser F; Alifano M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):497-505. PubMed ID: 32936316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.